Related Experiment Videos
Managing childhood atopic dermatitis
Alexander K C Leung1, Kirk A Barber
1Department of Pediatrics, University of Calgary, Alberta, Canada.
Insights
Atopic dermatitis treatment is evolving. Topical immunomodulators offer a safe alternative to corticosteroids for managing this common childhood skin condition.
Area of Science:
- Dermatology and Immunology
Background:
- Atopic dermatitis is a chronic inflammatory skin condition affecting up to 20% of school-aged children.
- It significantly impacts patients' quality of life.
- Current management includes trigger avoidance, skin care, and corticosteroids for flares.
Purpose of the Study:
- To evaluate topical immunomodulators as an alternative to corticosteroids for atopic dermatitis.
- To assess the safety and efficacy of these new agents, particularly in pediatric populations.
Main Methods:
- Review of existing literature on atopic dermatitis treatments.
- Comparison of safety and efficacy profiles of corticosteroids versus topical immunomodulators (tacrolimus, pimecrolimus).
Main Results:
- Corticosteroids have short-term safety but potential long-term adverse effects.
- Topical immunomodulators demonstrate beneficial and safe profiles in both adults and children.
Conclusions:
- Topical immunomodulators represent a significant advancement in atopic dermatitis management.
- These agents offer a safe and effective alternative to chronic corticosteroid use, especially for children.
Abstract:
Atopic dermatitis, a chronic inflammatory skin disorder that affects up to 20% of school-aged children, can profoundly influence quality of life. Basic therapy consists of avoidance of triggering factors and optimal skin care. Until now, corticosteroids have been the usual treatment for acute flares. Short-term safety profiles are reasonable, but long-term use of corticosteroids may involve significant adverse effects. Topical immunomodulators (tacrolimus and pimecrolimus) are beneficial and safe for adults and children and represent a major new alternative to chronic corticosteroid use, especially in children.